AstraZeneca Pharma India (NSE:ASTRAZEN) Tax Provision: ₹-647 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
93 GF Score
Price ₹8,198.50
GF Value ₹10,976.58
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India Tax Provision?

AstraZeneca Pharma India NSE:ASTRAZEN -1.12% 93 Tax Provision is ₹-647 Mil as of Mar. 2026. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 93/100 and a GF Value™ of ₹10,976.58 (Modestly Undervalued). The stock has 4 warning signs investors should review.

AstraZeneca Pharma India's tax provision for the three months ended in Mar. 2026 was ₹-133 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-647 Mil.

AstraZeneca Pharma India Tax Provision Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India Tax Provision Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -214.40 -348.10 -580.30 -406.20 -646.80

AstraZeneca Pharma India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -202.20 -188.70 -186.00 -139.50 -132.60
NSE:ASTRAZEN
93GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-647 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of ₹-647 Mil mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Tax Provision of ₹-647 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on AstraZeneca Pharma India and its competitors.
Is AstraZeneca Pharma India's Tax Provision too high?
AstraZeneca Pharma India's current Tax Provision is ₹-647 Mil. Overall, AstraZeneca Pharma India has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Tax Provision compare to ZTS and UTHR?
AstraZeneca Pharma India's Tax Provision of ₹-647 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on AstraZeneca Pharma India and its competitors. AstraZeneca Pharma India's current Tax Provision is ₹-647 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,976.58, compared to a current price of ₹8,198.50 — trading 25.3% below its estimated fair value. The current Tax Provision is ₹-647 Mil. AstraZeneca Pharma India's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Tax Provision is ₹-647 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹8,198.50 is trading 25.3% below its estimated GF Value™ of ₹10,976.58. GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.

Key valuation signals for NSE:ASTRAZEN:

  • Tax Provision: ₹-647 Mil
  • GF Value™: ₹10,976.58 vs. price of ₹8,198.50 (25.3% below fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
93GF Score

Get the complete analysis for NSE:ASTRAZEN

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,198.50
Price
₹10,976.58
GF Value